secwatch.observer — SEC 8-K summary
======================================

Issuer:     Invivyd, Inc. (IVVD)
CIK:        0001832038
Form:       8-K
Filed at:   2025-03-20T23:59:59+00:00
Accession:  0000950170-25-042331
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Invivyd Q4 2024 PEMGARDA revenue $13.8M (+48% QoQ); FY2024 net loss $169.9M; FDA rejects EUA expansion for treatment
--------------------------------------------------------------------------------

- Q4 2024 net product revenue $13.8M, up 48% from Q3 $9.3M; full-year 2024 net product revenue $25.4M.
- Cash and cash equivalents $69.3M at Dec 31, 2024; targeting near-term profitability by end of 1H 2025 with existing cash and expected revenue growth.
- FDA declined request to expand PEMGARDA EUA for treatment of mild-to-moderate COVID-19 in immunocompromised; Invivyd submitted reconsideration request.
- Phase 1 data for VYD2311 shows average 17-fold greater neutralization potency than pemivibart; commercial mfg substantially completed.
- Net loss for 2024 $169.9M ($1.43 per share) vs $198.6M ($1.81 per share) in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832038/000095017025042331/0000950170-25-042331-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832038/000095017025042331/ivvd-20250320.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-042331

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer